Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs

Julie Butters; Alex Brown; Liddy Griffith; Susan Kim; Stephen J. Nicholls

doi:10.1007/s40256-017-0231-6

Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs

Julie Butters, Alex Brown, Liddy Griffith, Susan Kim, Stephen J. Nicholls^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

2 Citations (Scopus)

Abstract

While statins have formed the cornerstone of strategies for cardiovascular prevention, the residual risk related to low-density lipoprotein cholesterol (LDL-C) and other lipoprotein factors provides a landscape for development of new therapies. However, a number of lipid-modifying therapies have failed to reduce cardiovascular event rates in contemporary clinical trials of statin-treated patients. The factors considered in outcome measure selection for clinical trials of novel lipid-lowering therapies are reviewed. Evaluation of lipid-modifying drugs in clinical trials spans a spectrum from their effects on conventional circulating lipid parameters through to their impact on atherosclerotic plaque and ultimately clinical outcomes. The design of these trials has an important impact on the result and ultimate interpretation of these studies.

Original language	English
Pages (from-to)	447-452
Number of pages	6
Journal	American Journal of Cardiovascular Drugs
Volume	17
Issue number	6
DOIs	https://doi.org/10.1007/s40256-017-0231-6
Publication status	Published - 1 Dec 2017
Externally published	Yes

Access to Document

10.1007/s40256-017-0231-6

Cite this

@article{df46800d6147478eaccb7851a609e8e7,

title = "Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs",

abstract = "While statins have formed the cornerstone of strategies for cardiovascular prevention, the residual risk related to low-density lipoprotein cholesterol (LDL-C) and other lipoprotein factors provides a landscape for development of new therapies. However, a number of lipid-modifying therapies have failed to reduce cardiovascular event rates in contemporary clinical trials of statin-treated patients. The factors considered in outcome measure selection for clinical trials of novel lipid-lowering therapies are reviewed. Evaluation of lipid-modifying drugs in clinical trials spans a spectrum from their effects on conventional circulating lipid parameters through to their impact on atherosclerotic plaque and ultimately clinical outcomes. The design of these trials has an important impact on the result and ultimate interpretation of these studies.",

author = "Julie Butters and Alex Brown and Liddy Griffith and Susan Kim and Nicholls, {Stephen J.}",

note = "Publisher Copyright: {\textcopyright} 2017, Springer International Publishing Switzerland.",

year = "2017",

month = dec,

day = "1",

doi = "10.1007/s40256-017-0231-6",

language = "English",

volume = "17",

pages = "447--452",

journal = "American Journal of Cardiovascular Drugs",

issn = "1175-3277",

publisher = "Adis International Ltd",

number = "6",

}

TY - JOUR

T1 - Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs

AU - Butters, Julie

AU - Brown, Alex

AU - Griffith, Liddy

AU - Kim, Susan

AU - Nicholls, Stephen J.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - While statins have formed the cornerstone of strategies for cardiovascular prevention, the residual risk related to low-density lipoprotein cholesterol (LDL-C) and other lipoprotein factors provides a landscape for development of new therapies. However, a number of lipid-modifying therapies have failed to reduce cardiovascular event rates in contemporary clinical trials of statin-treated patients. The factors considered in outcome measure selection for clinical trials of novel lipid-lowering therapies are reviewed. Evaluation of lipid-modifying drugs in clinical trials spans a spectrum from their effects on conventional circulating lipid parameters through to their impact on atherosclerotic plaque and ultimately clinical outcomes. The design of these trials has an important impact on the result and ultimate interpretation of these studies.

AB - While statins have formed the cornerstone of strategies for cardiovascular prevention, the residual risk related to low-density lipoprotein cholesterol (LDL-C) and other lipoprotein factors provides a landscape for development of new therapies. However, a number of lipid-modifying therapies have failed to reduce cardiovascular event rates in contemporary clinical trials of statin-treated patients. The factors considered in outcome measure selection for clinical trials of novel lipid-lowering therapies are reviewed. Evaluation of lipid-modifying drugs in clinical trials spans a spectrum from their effects on conventional circulating lipid parameters through to their impact on atherosclerotic plaque and ultimately clinical outcomes. The design of these trials has an important impact on the result and ultimate interpretation of these studies.

UR - http://www.scopus.com/inward/record.url?scp=85018829977&partnerID=8YFLogxK

U2 - 10.1007/s40256-017-0231-6

DO - 10.1007/s40256-017-0231-6

M3 - Review article

SN - 1175-3277

VL - 17

SP - 447

EP - 452

JO - American Journal of Cardiovascular Drugs

JF - American Journal of Cardiovascular Drugs

IS - 6

ER -

Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs

Abstract

Access to Document

Other files and links

Fingerprint

Cite this